Aiosyn lands funding for AI-driven cancer diagnostics

Aiosyn, a Dutch medical software company, has secured a €2.4 million funding round led by investors TNO Ventures, Oost NL, LUMO Labs, and Health Innovations. The funding, along with a new strategic partnership with the Netherlands Institute of Applied Scientific Research (TNO), will enable Aiosyn to accelerate the development and rollout of its AI-driven diagnostic solutions for cancer care, thereby transforming clinical decision-making for patients.

Aiosyn, specializing in AI-powered precision pathology software, targets both cancer and kidney diseases, integrating its solutions into standard pathology workflows. Their technology offers enhanced insight into tumor diagnostics and can also simplify and accelerate the drug discovery and development process.

Patrick de Boer, CEO and co-founder of Aiosyn, explains: “This funding marks a major milestone for Aiosyn and reinforces our mission to bring AI innovation into clinical practice and invest in a new generation of AI algorithms that transform clinical decision-making for cancer patients”

Strategic partnership with TNO

In conjunction with the funding, Aiosyn announced a strategic partnership with TNO, the Netherlands' largest research and technology organization. This collaboration will allow Aiosyn to leverage TNO's research facilities and network to accelerate the clinical validation and market readiness of its AI software. Simultaneously, TNO will gain access to Aiosyn's AI expertise, enhancing its position in preclinical contract research services. Hans Boumans, Director of TNO Ventures, emphasized that Aiosyn embodies the kind of innovation TNO is proud to support, aligning with TNO's strategy to help Dutch tech companies scale globally.

“Aiosyn exemplifies the kind of bold, forward-thinking innovation that TNO is proud to support, delivering on TNO’s strategy to help Dutch tech companies scale globally and lead in key technologies”, said Hans Boumans, Director of TNO Ventures.

Scenexus emerges as TNO spin-off, securing a € 1.6 million investment 

Scenexus is the inaugural investment from the recently established LUMO Rise Fund.

Read More

AI in diagnostics

Sven Bakkes, Founding Partner at LUMO Labs, adds, “The potential of Artificial Intelligence in diagnostics is immense. Aiosyn is a great example of how automating complex diagnostic tasks, can improve care for cancer patients. We are pleased to continue our support to accelerate the development and rollout of their solutions.

Earlier this year, Aiosyn's AI-driven software for breast cancer detection, Aiosyn Mitosis Breast, received the CE mark, a European conformity certification. This certification signifies a major advancement in pathology, enhancing diagnostic accuracy and efficiency. The algorithm, validated in a multi-center clinical study, promises up to 60% time savings per slide and a 15% boost in productivity. Furthermore, it has the potential to improve diagnostic consistency by 32.6%, with over 90% of clinical study participants eager to integrate it into their workflows. This aligns with broader healthcare objectives, potentially contributing to improved breast cancer detection and treatment outcomes.